Frontlight ResearchEarly access
CompletedPhase 2
Evaluation of New Diagnostic Tool Using Fluorescence to Detect High-grade Vulvar Intraepithelial Neoplasia
Key facts
- Who runs it
- Institut de Cancérologie de Lorraine
- Where
- France1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 17 people enrolled
- Started
- 29 Nov 2021
- Ended
- 25 May 2025
- Type of study
- Interventional
- Treatments tested
- Metvixia Topical Cream
- Record updated
- 24 July 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- Patient aged 18 and over,
- With isolated high-grade vulvar intraepithelial neoplasia OR associated with invasive cancer proven histologically by biopsy
- Naive of any vulvovaginal treatment (surgery or radiotherapy)
- No metastases
- WHO <or equal to 3
- Contraception method for women of childbearing potential
- Patient affiliated to the social security scheme
- Patient who understood, signed and dated the information note and the
- consent form,
- Patient able and willing to follow all study procedures in accordance with the protocol
Who cannot take part
- Any previous vulvovaginal treatment (surgery or radiotherapy)
- Associated pathology that may prevent the patient from receiving METVIXIA application and light exposure
- History of hypersensitivity to the active substance methyl aminolevulinate or to any of the components of the drug (including peanut oil and refined almond oil), soybean or peanut
- Metastatic disease
- Patient undergoing treatment for any other invasive cancer
- Ulceration or hyperpigmented lesions of the vulva
- Patient with porphyria
- Pregnant, likely to be or breastfeeding patient
- Patient deprived of liberty or under guardianship (including guardianship)
- Inability to undergo medical monitoring of the trial for geographic, social or psychological reasons
- Patient already included in another therapeutic trial with an experimental molecule,
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study is a single-center propsective clinical trial to assess the ability of fluorescence techniques to mark high-grade vulvar intraepithelial neoplasias including high-grade vulvar squamous intraepithelial lesions and differentiated vulvar intraepithelial neoplasias following 3 hours Metvixia application.
The group in the trial
- Metvixia application for Photodynamic diagnosisTreatment being tested
Patients who benefit Metvixia application to the vulva to realize fluorescence guided biopsies (Photodynamic diagnosis).
Treatment: Metvixia Topical Cream
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Evaluation of the Ability of PpIX Fluorescence to Mark High-grade Vulvar Intraepithelial Neoplasia Following the Methyl Aminolevulinate (Metvixia®) Application
- Record updated
- 24 July 2025